Vor Ort
Merkzettel Warenkorb
  • Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
  • Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
Band 89

Tumor Antigenicity and Approaches to Tumor Immunotherapy An Outline

Aus der Reihe Current Topics in Microbiology and Immunology

49,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

18.10.2011

Verlag

Springer Berlin

Seitenzahl

86

Maße (L/B/H)

24,4/17/0,6 cm

Gewicht

189 g

Auflage

1980

Sprache

Englisch

ISBN

978-3-642-67499-0

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

18.10.2011

Verlag

Springer Berlin

Seitenzahl

86

Maße (L/B/H)

24,4/17/0,6 cm

Gewicht

189 g

Auflage

1980

Sprache

Englisch

ISBN

978-3-642-67499-0

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
  • Produktbild: Tumor Antigenicity and Approaches to Tumor Immunotherapy
  • 1 Tumor-Associated Antigenicity and Host Responsiveness: Basic Questions and Considerations.- 2 Tumor Etiology and Antigenicity.- 2.1 Tumors Known to be Induced by Viruses.- 2.2 Tumors Known to be Induced by Chemical Agents and by Other Carcinogenic Stimuli.- 2.3 “Spontaneous” Tumors, with No Obvious Viral Etiology (Animal und Human).- 3 Approaches to Immunotherapy.- 3.1 Active “Nonspecific Immunogherapy” with Immunomodulating Agents.- 3.1.1 Loci of Immunomodulator Influence on Antitumor Immune Responses.- 3.1.1.1 Nonspecific Potentiation of Specific Responsiveness to Tumor associated Antigens.- 3.1.1.2 Nonspecific “Spillover” of Potentiated Specific Responsiveness to TAAs.- 3.1.1.3 Nonspecific Potentiation of Specific Immunological Reactions Against Antigens Other than TAAs.- 3.1.1.4 Antigenic Cross-reactivity Between Microbial Immunomodulators and Tumor Cells.- 3.1.1.5 Direct Nonspecific Activation of Immunocytes and Its Nonspecific Consequences.- 3.1.1.6 Nonimmunological Loci of Action of Substances with Immunomodulator Properties.- 3.1.1.7 General Comments.- 3.1.2 Nonliving Immunomodulators of Microbial Origin.- 3.1.3 Intralesional and Regional Versus Distal Immunotherapeutic Administration of Immunomodulators.- 3.1.4 Combined Modalities of Treatment Including Intervention with Nonspecific Immunomodulators.- 3.1.5 Possible Advantages Inherent in the Nonspecific Approach to Tumor Immunotherapy.- 3.2 Active Specific Immunization with Tumor Cell Antigens.- 3.2.1 General Considerations.- 3.2.2 Modification of Tumor Cell Antigens.- 3.2.3 Other Possible Means of Specific Immunization.- 3.3 Passive and Adoptive Immunological Intervention.- 3.3.1 General Considerations.- 3.3.2 In Vitro Generation of Cytotoxic Effector Cells Against Tumors.- 3.3.3 Potentiation of the In Vitro Generation of Cytotoxic Effector Cells.- 3.3.4 In Vitro Production of Antibodies and Its Potentiation.- 3.3.5 Possibilities and Problems of Clinical Application.- 4 Concluding Remarks.- 4.1 Immune Surveillance and Immunological Intervention: Hypothesis and Empiricism.- 4.2 Key Aspects of the Approaches to Tumor Immunotherapy.- 4.3 Goals and Expectations.- 4.4 Experimental Perspectives.- 4.5 Immunological Capacity, Immunological Monitoring, and Susceptibility to Neoplastic Disease.- 4.6 Immunological and Nonimmunological Resistance to Progressive Neoplasia.- 4.7 Coda.- 5 Notes added in Press.- Acknowledgements.- References.